The level of IL-6 was associated with sleep disturbances in patients with major depressive disorder

Min Wang,1,2 Jinxue Wei,1,2 Xiao Yang,1,2 Peiyan Ni,1,2 Yingshen Wang,1,2 Liansheng Zhao,1,2 Wei Deng,1,2 Wanjun Guo,1,2 Qiang Wang,1,2 Tao Li,1,2 Xiaohong Ma1,2

1Mental Health Center and Psychiatric Laboratory, West China Hospital of Sichuan University, Chengdu, People’s Republic of China; 2Huaxi Brain Research Center, West China Hospital of Sichuan University, Chengdu, People’s Republic of China

Keywords: major depression disorder, inflammation, cytokine, interleukin-6, sleep disturbances

Introduction

Major depression disorder (MDD) is an enervating mental disorder that features depressed mood, slow thinking, and decreased volitional activity and is accompanied by sleep disorders, decreased appetite, and manifestations of autonomic nervous dysfunction.1 MDD has an overall impact on global disease and is predicted to become the leading burden of disease by the year 2020.2 While effective treatments based on various neurotransmitter systems are available, approximately one-third of patients suffering from depression encompass a poor response to conventional antidepressant therapies.3 Consequently, it is urgent to develop new theoretical frameworks for understanding the development and progression of depression in order to formulate targeted and curative treatments. Accumulating evidence implicates that activation of the immune-inflammatory pathways is an important contributor to the development of MDD and shows the immune system as a feasible therapeutic target that may be more relevant to the pathogenesis of mood disorders in specific subpopulations.4–7 Inflammatory biomarkers have been demonstrated to cross the
blood–brain barrier and thus interfere with a wide range of aspects of the pathophysiology of MDD, such as neuroplasticity, neurotransmitter metabolism, neuroendocrine function, and apoptosis of neurocyte. Nevertheless, numerous literature have shown that changes in the levels of inflammatory cytokine do not always present positive results in the development and treatment of depression. Given this, there is a hypothesis that inflammation is not prevalently present in, but only limited to, specific subgroups of individuals with MDD.

Inflammation in depressed patients is a special pathological type since its inflammatory markers are not as elevated as those of bacterial infections. Some researchers hold that MDD is mainly induced by psychosocial stress in the subgroup undergoing chronic low-grade inflammation. Stress-induced neuroendocrine mechanisms, including glucocorticoid resistance (GR), the hypothalamic–pituitary–adrenal (HPA) axis hyperactivity and the sympathetic nervous system (SNS)-mediated dysfunction, may function as pivotal immunological interfaces between stress and inflammation. In a stressful environment, central nervous fibers release the neurotransmitters into lymphoid organs and peripheral tissues in which inflammatory reactions take place, and hypothalamus cytokine receptors trigger the production of glucocorticoids by activating the HPA axis. A research showed that psychological changes associated with acclimatization to stress dynamics are persistent and cumulative changes occur in the structure of the CNS. Stress-induced GR is a typical biological abnormality and has been correlated with increased inflammation in depressed patients. In addition, there are a good deal of studies that reported increased levels of proinflammatory cytokines, including IL-6, IL-1β, interferon (INT)-α, and tumor necrosis factor (TNF)-α in depressed patients. Noteworthy, researches have shown that IL-6 is involved in a variety of physiological systems, including the activation of HPA axis, corticotrophin-releasing hormone activity, apoptotic pathways and the induction of oxidative stress, all of which are relevant to the pathophysiology of MDD. In general, these data support the assumption that the inflammatory cytokines may be critical immunological points for the connection of stress-induced risk signals that ultimately drive inflammatory responses related to depression.

In addition, an association has been observed between chronic low-grade inflammation and the severity of depression symptom and even particular depressive psychopathology. For instance, compelling evidence has demonstrated that lower sleep efficiency is associated with elevated inflammatory biomarkers. A study showed that peripheral inflammatory markers, including elevated IL-6 and monocyte chemotactic protein, were consistently associated with psychomotor speed in MDD. Another study showed that increased appetite was related to C-reactive protein (CRP) and TNF-α in the context of a depressive episode. In a prospective study involving 190 patients who had contracted hepatitis C virus and initiation of standard treatment with IFN-α, the authors found that during receiving chronic IFN-α treatment, the rate of meeting diagnostic criteria for MDD was up to 50%, and psychomotor retardation and somatic symptoms may reflect a greater inflammatory state before treatment. Nevertheless, some symptoms may be more strongly correlated to inflammation than others, some may be the result of inflammation, and others may indicate increases in inflammation. Despite the large bulk of literature linking depression with inflammation, the associations of inflammation with specific depression symptoms remain largely unknown. In addition, only few clinical research involving patients with mood disorders have examined whether proinflammatory cytokines were differently related to specific depression symptoms and the results were inconsistent.

Therefore, to investigate cytokines in patients with MDD, we examined the concentrations of the proinflammatory cytokines IL-1β, IL-6, TNF-α, INF-α2, and INF-γ in patients with moderate-to-major depression. What is more, we aimed to investigate the relationships between specific depression symptoms and proinflammatory cytokines.

**Methods**

**Subjects**

The study involved 44 patients with depression and 54 sex- and age-matched healthy controls who were recruited from the Mental Health Center of West China Hospital of Sichuan University. Participants were Han Chinese aged between 18 and 60 years who were physically healthy with Wechsler’s intelligence test scores being >90. The diagnosis was consistent with the criteria for MDD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The severity of depression was assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17), which evaluated symptoms in five dimensions, namely anxiety, weight, cognition, slowness, and sleep disorder. The total scores of HAMD-17>17 were obtained. The 14-item Hamilton anxiety rating scale (HAMA-14) was also used for evaluation.
Participants were excluded if they: 1) had neurogenic diseases or a history of endocrine, autoimmune, metabolic disorders; 2) had other DSM-IV axis I and II diseases, such as bipolar disorder, schizophrenia, substance abuse, or a family history of mental illness; 3) were taking hormone, antibiotics, or anti-inflammatory medications; or 4) were pregnant or lactating.

All participants provided informed written consent. The study was approved by the Institutional Ethics Committee of Sichuan University. All study procedures were in accordance with the Declaration of Helsinki.

Cytokine detections
Peripheral blood of all participants was collected by venipuncture. The samples were placed in EDTA anticoagulant tubes for laboratory tests. Centrifugation was performed at 2,000×g for 5 mins. After that, the upper plasma was moved to a fresh tube and then stored at −80°C.

A multiplexed flow cytometric assay using a Milliplex kit (HCYTOMAG-60K; Millipore, Billerica, MA, USA) was applied to measure the concentrations of proinflammatory cytokines including IL-1β, IL-6, TNF-α, INF-α, and INF-γ. Their levels were expressed in pg/mL. The assays were conducted by Bio-atom Biotechnology (Chengdu, China) following the instructions provided by the manufacturer.

Statistical analysis
Statistical analysis was performed by means of the SPSS 25.0 software package. All data are presented as mean ± SE unless otherwise stated. \( \chi^2 \) test was used to compare categorical variables for demographic and clinical characteristics. Student’s \( t \)-test was applied for continuous variables. The Mann–Whitney U test was applied to compare the concentrations since the concentrations of cytokine in plasma did not follow a Gaussian distribution. The Spearman correlation test was used to ascertain the associations between the cytokines’ concentrations and the five syndrome scores of the HAMD-17. All P-values <0.05 were considered statistically significant. We did not correct for multiple testing.

Results
Demographic and clinical characteristics of the participants
The study included 44 subjects with depression (20 men and 24 women) and 54 healthy individuals (19 men and 35 women). The average age of the participants having MDD and healthy controls was 29.27±10.83 and 29.67±10.29 years, respectively. Age (\( P=0.86 \)), gender (\( P=0.41 \)), and body mass index (BMI) (\( P=0.158 \)) between the two groups were not different between depressed patients and their controls. The total HAMD and HAMA scores of all the participants having MDD were 22.60±4.93 and 14.44±6.88, respectively (Table 1).

Plasma levels of IL-1β, IL-6, TNF-α, INF-α, and INF-γ
The plasma concentrations of IL-1β, IL-6, TNF-α, INF-α2, and INF-γ in all participants are presented (Table 2). The levels of IL-6 were significantly higher in MDD patients than in controls (\( P=0.031 \)), while the differences for IL-1β, TNF-α, INF-α2, and INF-γ were not significant (\( P=0.627, P=0.178, P=0.347, \) and \( P=0.169 \), respectively).

Associations between pro-inflammatory cytokines and specific depression symptoms in MDD patients
A significantly positive association was observed between IL-6 and sleep disturbance among MDD patients (\( r=0.329, \)

Table 1: Demographic and clinical characteristics of 98 participants

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>MDD patients</th>
<th>HC</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n = 44)</td>
<td>(n = 54)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males (n)</td>
<td>20</td>
<td>19</td>
<td>0.407</td>
</tr>
<tr>
<td>Age (years)</td>
<td>29.27±10.83</td>
<td>29.67±10.29</td>
<td>0.855</td>
</tr>
<tr>
<td>Education year</td>
<td>13.11±3.05</td>
<td>14.80±3.84</td>
<td>0.02</td>
</tr>
<tr>
<td>BMI</td>
<td>20.73±3.06</td>
<td>21.63±3.18</td>
<td>0.158</td>
</tr>
<tr>
<td>Age of onset (years)</td>
<td>27.35±10.67</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of episode</td>
<td>1.79±2.21</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Disease duration (months)</td>
<td>50.7±64.80</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Duration the current episode (months)</td>
<td>4.88±5.01</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HAMA total scores</td>
<td>14.44±6.88</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HAMD17 total scores</td>
<td>22.60±4.93</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anxiety/somatization (scores)</td>
<td>4.65±1.63</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Weight (scores)</td>
<td>1.16±0.90</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cognitive disturbance (scores)</td>
<td>2.44±1.61</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Retardation (scores)</td>
<td>3.58±1.50</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sleep disturbance (scores)</td>
<td>6.70±2.64</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Notes: Data presented as mean ± standard deviation unless otherwise stated. Anxiety/somatization, HAMD 10, 11, 12, 15, 17; Weight, HAMD 16; Cognitive disturbance, HAMD 2, 3, 9; Retardation, HAMD 1, 7, 8, 14; Sleep disturbance, HAMD 4, 5, 6. Abbreviations: MDD, major depressive disorder; HC, healthy control; BMI, body mass index; HAMA, Hamilton Anxiety Rating Scale; HAMD, Hamilton Depression Rating Scale.
suggested that the concentrations of IL-6 in cerebrospinal fluid in individuals with MDD were higher than those in controls. An increase of IL-6 in peripheral blood may reflect a relative sensitized inflammatory response, which may suggest a state of mild inflammation at the brain levels. Another longitudinal study manifested that elevated IL-6 increases the risk for depressive symptoms over time. Inflammation may also give rise to treatment non-response by affecting the neurotransmitter systems associated with antidepressant efficacy, and higher IL-6 levels were proved to be associated with a greater number of treatment failures.

However, the IL-6 levels changes were inconsistent in patients with MDD. Some studies found there was no difference in IL-6 levels between patients with MDD and their controls. One possible explanation for such inconsistency was that inflammatory marker levels in people with major depression may be higher than those with mild depression. This possibility helps explain why IL-6 levels were significantly higher in MDD patients than in controls in the present study: our sample consisted primarily of patients with moderate-to-severe depression.

Multiple lines of evidence have shown that inflammatory markers are associated with specific depressive symptoms. Our results confirm that lower sleep efficiency was associated with higher circulating levels of IL-6 in midlife women. Elevated inflammatory cytokines in patients can lead to various forms of sleep disturbance in other diseases, such as schizophrenia, sleep apnea-hypopnea syndrome (SAHS), type 2 diabetes, and cardiovascular events. Because inflammatory responses can be triggered by obesity, hypoxia, and hyperlipidemia, levels of pro-inflammatory factors may be elevated. One thorny question is whether inflammation causes sleep disorders or whether sleep disorders cause inflammation. Based on our study, we propose that for patients with elevated inflammatory

### Table 2 The median of five cytokines concentration in patients with MDD and healthy controls

<table>
<thead>
<tr>
<th>Cytokine (pg/ml)</th>
<th>MDD patients (n=44)</th>
<th>HC (n=54)</th>
<th>Z</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1β</td>
<td>1.73</td>
<td>1.59</td>
<td>-0.87</td>
<td>0.627</td>
</tr>
<tr>
<td>IL-6</td>
<td>1.09</td>
<td>0.82</td>
<td>-2.113</td>
<td>0.031*</td>
</tr>
<tr>
<td>TNF-α</td>
<td>7.05</td>
<td>6.21</td>
<td>-0.802</td>
<td>0.178</td>
</tr>
<tr>
<td>IFN-α2</td>
<td>5.2</td>
<td>3.62</td>
<td>-0.859</td>
<td>0.347</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>12.94</td>
<td>9.87</td>
<td>-0.866</td>
<td>0.169</td>
</tr>
</tbody>
</table>

Notes: *P<0.05.
Abbreviations: MDD: Major Depressive Disorder; HC: Healthy control; IL, interleukin; TNF, tumor necrosis factor; IFN, interferon.

### Table 3 Relationship between cytokine concentrations and the five syndrome scores

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Anxiety/somatization</th>
<th>Weight</th>
<th>Cognitive disturbance</th>
<th>Retardation</th>
<th>Sleep disturbance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>r</td>
<td>P</td>
<td>r</td>
<td>P</td>
<td>r</td>
</tr>
<tr>
<td>IL-1β</td>
<td>-0.111</td>
<td>0.477</td>
<td>-0.108</td>
<td>0.491</td>
<td>0.034</td>
</tr>
<tr>
<td>IL-6</td>
<td>-0.15</td>
<td>0.337</td>
<td>0.024</td>
<td>0.877</td>
<td>0.095</td>
</tr>
<tr>
<td>TNF-α</td>
<td>-0.164</td>
<td>0.293</td>
<td>0.071</td>
<td>0.651</td>
<td>0.115</td>
</tr>
<tr>
<td>IFN-α2</td>
<td>-0.011</td>
<td>0.944</td>
<td>-2.1</td>
<td>0.177</td>
<td>-0.22</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>-0.077</td>
<td>0.624</td>
<td>0.081</td>
<td>0.606</td>
<td>0.029</td>
</tr>
</tbody>
</table>

Notes: *P<0.05; r, Spearman correlation coefficient.
Abbreviations: IL, interleukin; TNF, tumor necrosis factor; IFN, interferon.

### Discussion

Our results documented that the level of IL-6 was increased in patients with MDD when compared with healthy controls. However, the levels of INF-α2, INF-γ, IL-1β, and TNF-α were not significantly different between the two groups. The association between higher IL-6 and sleep disturbance was significant among MDD patients. A significant difference in IFN-α2 levels was observed between patients with MDD and healthy controls. Interestingly, we also found a significant correlation between IFN-α2 and retardation.

Our results regarding IL-6 were consistent with a number of prior reports by other researchers. A previous study showed that the concentrations of the serum IL-6 in depressed patients were significantly higher than that in the controls. A recent meta-analysis involving 42 studies supported this finding, with significantly elevated IL-6 levels in participants with MDD compared with healthy controls. A more recent meta-analysis also
cytokines, medical staff should be aware of the occurrence of sleep disorders. Large prospective studies should be conducted to provide stronger evidence to support the inflammatory hypothesis of depression.

Our study also found a significant correlation between IFN-α2 and retardation, although no difference was observed in the level of INF-α2 between MDD patients and healthy controls. Our findings are consistent with the study in which no difference was found between MDD patients and healthy controls. INF-α2 and IFN-γ are both proinflammatory factors in the INT family. In our study, no difference in the levels of INF-γ was found between the two groups. A meta-analysis involving 17 studies indicated that the levels of IFN-γ were reduced in patients with MDD compared to the healthy controls. We found a significantly positive correlation between IFN-α2 and retardation. Previous studies have shown that IFN-α injections may trigger depression in patients infected with hepatitis C virus, and psychomotor retardation, and somatic symptoms may play important roles.

Limitations

However, this study has several weaknesses that warrant consideration. First, the study was not representative enough because it had a small sample size, and all patients exhibited a similar severity of moderate-to-severe depression. These two factors decreased the study’s statistical power, and we did not correct for multiple testing. Therefore, it is better for future studies to involve a larger sample size given the heterogeneity of clinical manifestations of depression. Second, the cross-sectional study did not allow us to draw any conclusions regarding cause-to-effect relationships. Longitudinal studies should be performed to observe the causal relationships between inflammation and specific depressive symptoms. Finally, the scale was simplified, and the description of symptoms was not comprehensive and accurate enough. Therefore, future studies can evaluate depressive symptoms using multiple scales simultaneously, such as the Montgomery depression scale and the self-rating depression scale.

Conclusion

In summary, elevated IL-6 level is observed in MDD patients. Besides, IL-6 may correlate with sleep disturbance. Further investigation may expand the sample size and increase scale category to confirm the results.

Acknowledgments

This research was supported by the National Natural Science Foundation of China (Grant No.: 81671344), and the 1.3.5 Project for Disciplines of Excellence, West China Hospital of Sichuan University (Grant No.: ZY2016103 and ZY2016203).

Author contributions

MW, XM, JW, and XY designed the study. MW performed the statistical analyses and wrote the initial draft of the manuscript. All of the authors contributed to data collection and analysis, critically revised the article and gave final approval of the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Disclosure

The authors report no conflicts of interest in this work.

References


17. Al-Hakeim HK, Al-Ramahi DA, Al-Dujaili AH. IL-6, IL-18, sIL-2R, and TNFalpha proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J Affect Disord. 2015;182:106–114. doi:10.1016/j.jad.2015.04.044


